Trial Profile
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 21 Apr 2022 Status changed from active, no longer recruiting to completed.
- 28 Jul 2020 Planned End Date changed from 31 Jul 2020 to 31 Mar 2022.
- 28 Jul 2020 Planned primary completion date changed from 31 Jul 2020 to 31 Mar 2022.